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To evaluate how a larger group of pathologists would assess this particular case, we performed a Web-based survey among pathologists at the Institute of Pathology of the Charité Medical University Berlin. In the survey, we presented the clinical information of a 54-year-old female patient with abdominal pain and the cytological image available in the paper, including the immunoprofile used at the initial diagnosis. We offered the answer choices: (a) gastric cancer, (b) pancreatico-biliary cancer, (c) colon cancer, (d) ovarian cancer, and (e) endometrial cancer. The 16 participating pathologists were unaware of the case report (ie, blinded to the context of the data provided). Twelve pathologists (75.0%) chose ovarian carcinoma as the most likely diagnosis, whereas 2 pathologists (12.5%) believed the tumor cells to be of gastric origin, and the remaining 2 (12.5%) favored a pancreatobiliary primary. Most participants commented that they would have requested further immunostains, including WT1 and PAX8. Therefore, although most pathologists had already suspected the correct diagnosis based on morphology alone, they-and also the pathologists in favor of gastric or pancreaticobiliary carcinoma-would have used additional immunostains that would have led them to the same (correct) diagnosis.
Finally, although we strongly agree with Chapman et al 1 that molecular profiling, in addition to providing important clinical information on actionable mutations beyond histology, might in certain morphologically and immunohistologically ambiguous cases help classify tumors in the future using the approach they present, we would like to point out that correct tumor typing in the present case would have been rather straightforward with conventional morphological assessment and a few additional standard immunostains without any further molecular profiling. Although it is evident that molecular profiling will play an increasing role in cancer precision medicine in the coming years, [4] [5] [6] [7] we believe that these time-consuming and costly methods should be carefully integrated with the current standards of histo-/cytomorphological and immunohistochemical workup to optimize diagnostics and patient care.
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